-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Le2VGDcBx/T0UOaAv6xwDRUfzOUC5SiZIhRJYg49XZyg2U7eCWSxCNVSvz50R1AO
 OmoLQz3GI9JqYP3uUMcTVQ==

<SEC-DOCUMENT>0000318306-07-000007.txt : 20070215
<SEC-HEADER>0000318306-07-000007.hdr.sgml : 20070215
<ACCEPTANCE-DATETIME>20070215152453
ACCESSION NUMBER:		0000318306-07-000007
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070215
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070215
DATE AS OF CHANGE:		20070215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACCESS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		07627132

	BUSINESS ADDRESS:	
		STREET 1:		2600 N STEMMONS FRWY
		STREET 2:		STE 176
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75207
		BUSINESS PHONE:		2149055100

	MAIL ADDRESS:	
		STREET 1:		2600 N STEMMONS FRWY
		STREET 2:		STE 176
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX CORP/WY
		DATE OF NAME CHANGE:	19831102
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>r8k-142.txt
<DESCRIPTION>FORM 8-K
<TEXT>
                            UNITED STATES
                  SECURITIES AND EXCHANGE COMMISSION
                        WASHINGTON, DC  20549


                                FORM 8-K

                             CURRENT REPORT

                PURSUANT TO SECTION 13 OR 15(d) OF THE
                    SECURITIES EXCHANGE ACT OF 1934


    Date of report (Date of earliest event reported): February 8, 2007



                       Access Pharmaceuticals, Inc.
           ------------------------------------------------------
           (Exact name of registrant as specified in its charter)


        Delaware                     0-9314                  83-0221517
- ------------------------    ------------------------    -------------------
(State of Incorporation)    (Commission File Number)    (I.R.S. Employer

                                                        Identification No.)


     2600 Stemmons Freeway, Suite 176, Dallas, Texas             75207
     -----------------------------------------------           ---------
        (Address of principal executive offices)               (Zip Code)


   Registrant's telephone number, including area code: (214) 905-5100
                                                       --------------


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:

/ / Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

/ / Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

/ / Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2 (b))

/ / Pre-commencement communications pursuant to Rule 13e-4(c)) under the
    Exchange Act (17 CFR 240.13e-4 (c))



<PAGE>
Item 5.02
Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.
- ------------------------------------------------------------------------

Effective February 8, 2007, the Board of Directors of Access
Pharmaceuticals, Inc. (the "Company") elected Estaban Cvitkovik, MD
as a member of the Company's Board of Directors. Dr. Cvitkovik also
assumed the title of Vice Chairman (Europe) as of that date.

Dr. Cvitkovik is currently a Senior Medical Consultant to AAIOncology,
an oncology focused CRO based in France. Recently, the oncology focused
CRO Cvitkovic & Associes Consultants, founded by Dr. Cvitkovic
11 years ago, was sold to AAIPharma to become AAIOncology. In addition,
he maintains a part-time academic practice including teaching at the
Beaujon and St. Louis hospitals in Paris. Dr. Cvitkovic is also
Scientific President of the FNAB, a foundation devoted to the
furthering of personalized cancer treatments. Together with a small
number of collaborators he recently co-founded Oncoethix, a biotech
company focused on licensing and co-development of anti-cancer
molecules. Dr. Cvitkovic has also held staff and academic
appointments at Memorial Sloan Kettering Cancer Center (New York),
Columbia Presbyterian (New York), Instituto Mario Negri (Milan),
Institute Gustave Roussy (Villejuif), and Hopital Paul St. Louis
(Paris).

Effective February 8, 2007, Stuart M. Duty resigned from the Board of
Directors.

Item 9.01
Financial Statements and Exhibits
- ---------------------------------

A press release is attached as Exhibit 99.1 to this report and is
Incorporated herein by this reference, in which the Company announced
its new director Estaban Cvitkovik, MD.


<PAGE>
                               SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.


                                          Access Pharmaceuticals, Inc.
                                                 (Registrant)

                                          By: /s/ Stephen B. Thompson
                                             ------------------
                                              Stephen B. Thompson
                                              Vice President and
                                              Chief Financial Officer
Dated February 15, 2007

                                  3
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>r8k-143.txt
<DESCRIPTION>PRESS RELEASE DATED FEBRUARY 8, 2007
<TEXT>
                            {Letterhead}
                             ACCESS NEWS

Contact: Company                                  Contact: Investor Relations
Stephen B. Thompson               Donald C. Weinberger/Alisa Steinberg (media)
Vice President, Chief Financial Officer          Wolfe Axelrod Weinberger LLC
(214) 905-5100                                                 (212) 370-4500

                                     Andrew Hellman, CEOcast, Inc. for Access
                                              Pharmaceuticals, (212) 732-4300

           ACCESS PHARMACEUTICALS APPOINTS ESTEBAN CVITKOVIC,M.D.
                  AS DIRECTOR AND VICE CHAIRMAN (EUROPE)

             Accomplished Physician in Registration of Leading
             Cancer Drugs to Enhamce Development of ProLindac(TM)

Dallas, TEXAS, February 8, 2007, ACCESS PHARMACEUTICALS, INC. (ACCP.OB)
announced today that Esteban Cvitkovic, M.D., a widely respected
physician who played a key role in the registration of leading cancer
drugs, has joined the Board of Directors and assumed the title of Vice
Chairman (Europe). Dr. Cvitkovic has more than thirty years of
international experience in oncology therapeutics, including clinical
research, clinical pharmacology, the design of single-agent and
combination regimens, disease-oriented therapeutic impact assessment,
and optimization of clinical efficacy.  Dr. Cvitkovic played a fundamental
role in the registration strategy and post-registration development for
cisplatin and oxaliplatin, and will be integral to the development of
ProLindac(TM), Access' novel DACH platinum prodrug.

"The clinical need and market potential for a platinum compound with a
differential efficacy profile and/or a better therapeutic index than
those that are currently available is the current reality since Eloxatin's
success.  I believe that ProLindac(TM) has the potential to be such a drug,"
stated Dr. Esteban Cvitkovic.  "I am very happy to be able to help Access
accomplish this goal and develop its existing portfolio."

                                -More-
<PAGE>
Access Pharmaceuticals, Inc.
Page 2

"We are extremely pleased to have Dr. Cvitkovic on the Access Board of
Directors," stated Mr. Jeffrey B. Davis, Chairman of Access' Board of
Directors. "Dr. Cvitkovic is widely regarded as one of the world's
leading developers of platinum therapeutics, has extensive experience
with DACH platinums, and his advice and counsel on the development of
ProLindac(TM) and our other oncology assets will be extremely important
to Access going forward."

Dr. Esteban Cvitkovic has authored more than 200 peer-reviewed articles
and 600 abstracts focused on therapeutic oncology development.  His
international career includes staff and academic appointments at Memorial
Sloan Kettering Cancer Center (New York), Columbia Presbyterian (New
York), Instituto Mario Negri (Milan), Institut Gustave Roussy (Villejuif),
Hopital Paul Brousse (Villejuif) and Hopital St. Louis (Paris). Recently,
the oncology-focused CRO Cvitkovic & Associes Consultants (CAC), founded
by Dr. Cvitkovic 11 years ago and which he developed from a small oncology
consultancy to a full-service CRO, was sold to AAIPharma to become
AAIOncology. Dr. Cvitkovic is currently a Senior Medical Consultant
to AAIOncology. In addition, he maintains a part-time academic practice
including teaching at the hospitals Beaujon and St Louis in Paris. Dr.
Cvitkovic is Scientific President of the FNAB, a foundation devoted to the
furthering of personalised cancer treatments. Together with a small number
of collaborators he has recently co-founded Oncoethix, a biotech company
focused on licensing and co-development of anti-cancer molecules.

About ProLindac(TM)
- -------------------
The Company's lead compound, ProLindac(TM), is a novel dach platinum prodrug
which has been shown to be active in a wide variety of solid tumors in both
preclinical models and in human trials. The Company believes that
ProLindac(TM)'s unique molecular design potentially could eliminate some of
the toxic neurological side effects seen in currently marketed Dach
platinums. The Company is currently enrolling patients in two Phase II
clinical trials, one in ovarian cancer and one in head and neck cancer, and
plans to initiate one or more additional Phase II trials, including one in
colorectal cancer in 2007.

About MuGard(TM)
- ----------------
The Company has received 510(k) clearance from the FDA to market MuGard(TM)
in the United States. MuGard(TM) is Access' proprietary oral rinse product
for the prevention and treatment of oral mucositis, the debilitating side-
effect which afflicts more than 40% of cancer patients undergoing radiation
and chemotherapy. There is currently no well- accepted treatment for
mucositis. Access is actively seeking marketing partners in Europe and
the US.

                                -More-
<PAGE>
Access Pharmaceuticals, Inc.
Page 3

About Cobalamin(TM)
- -------------------
The Company is actively pursuing developing clinical development of its
novel Cobalamin(TM) drug delivery technology, particularly as it pertains
to the oral delivery of large molecule drugs that are only currently
deliverable by injection or intravenous administration. Pre-clinical animal
studies utilizing Access' Cobalamin(TM) technology have demonstrated the
ability to deliver insulin by oral administration in therapeutic levels.
Access is actively seeking development partners in this area as well.

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that
develops and commercializes propriety products for the treatment
and supportive care of cancer patients. Access' products include
ProLindac(TM), currently in Phase II clinical testing of cancer and
MuGard(TM) for the treatment of patients with oral mucositis for
which marketing authorization has been allowed by the FDA. The Company
also has other advanced drug delivery technologies including
Cobalmin(TM)-mediated targeted delivery and oral drug delivery. For
additional information on Access Pharmaceuticals, please visit our website
at www.accesspharma.com.

This press release contains certain statements that are forward-looking
within the meaning of Section 27a of the Securities Act of 1933, as amended,
and that involve risks and uncertainties, including statements relating to
the value of our products in the market, our ability to achieve clinical and
commercial success and our ability to successfully develop marketed products.
These statements are subject to numerous risks, including but not limited to
the risks detailed in the Company's Annual Report on Form 10-K for the year
ended December 31, 2005 and other reports filed by us with the Securities
and Exchange Commission.

                                 # # #

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
